Lineage Debt Ratio from 2010 to 2025

LCTX Stock

USD 0.51 0.01 2.00%

Lineage Cell Debt Ratio yearly trend continues to be fairly stable with very little volatility. Debt Ratio will likely drop to 0.02 in 2025. During the period from 2010 to 2025, Lineage Cell Debt Ratio regression line of annual values had r-squared of 0.16 and arithmetic mean of 0.08. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

0.02220495

Current Value

0.0211

Quarterly Volatility

0.21779527

Credit Downgrade

Yuan Drop

Covid

Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 10 M, as well as many indicators such as Price To Sales Ratio of 10.06, Dividend Yield of 0.0015 or PTB Ratio of 1.37. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.

Check out the analysis of Lineage Cell Correlation against competitors.

Latest Lineage Cell's Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of Lineage Cell Therapeutics over the last few years. It is Lineage Cell's Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

Lineage Debt Ratio Regression Statistics

	Arithmetic Mean	0.08
	Geometric Mean	0.02
	Coefficient Of Variation	284.54
	Mean Deviation	0.10
	Median	0.02
	Standard Deviation	0.22
	Sample Variance	0.05
	Range	0.8847
	R-Value	(0.40)
	Mean Square Error	0.04
	R-Squared	0.16
	Significance	0.13
	Slope	(0.02)
	Total Sum of Squares	0.71

Lineage Debt Ratio History

	2025	0.0211
	2024	0.0222
	2023	0.0292
	2022	0.0315
	2021	0.0161
	2020	0.0306
	2019	0.0412

Other Fundumenentals of Lineage Cell Therapeutics

Cash Flow To Debt Ratio

Lineage Cell Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Intangible Assets	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Property Plant Equipment	Long Term Debt	Net Receivables	Long Term Debt Total	Short Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Good Will
Total Assets		0.88	-0.57	-0.7	0.06	0.57	0.77	0.82	0.48	-0.45	0.15	0.78	-0.81	0.29	0.87	0.63	-0.1	0.46	0.09	0.23	0.58	-0.43	0.38	0.39	-0.14
Total Stockholder Equity	0.88		-0.34	-0.52	0.07	0.21	0.51	0.69	0.14	-0.31	-0.12	0.94	-0.71	0.05	0.83	0.59	-0.3	0.26	0.01	0.21	0.54	-0.34	0.2	0.22	-0.09
Net Debt	-0.57	-0.34		0.57	0.21	-0.55	-0.65	-0.57	-0.58	0.15	-0.17	-0.25	0.57	-0.45	-0.51	-0.3	-0.12	-0.31	-0.1	0.37	-0.13	0.36	-0.12	-0.49	0.41
Retained Earnings	-0.7	-0.52	0.57		0.14	-0.71	-0.71	-0.97	-0.67	0.14	-0.55	-0.31	0.79	-0.67	-0.84	-0.67	0.17	-0.21	0.17	-0.34	-0.52	0.88	-0.07	-0.84	0.46
Accounts Payable	0.06	0.07	0.21	0.14		-0.19	-0.07	-0.11	-0.31	-0.38	-0.17	0.16	-0.12	-0.41	0.05	-0.07	0.04	0.12	0.25	-0.01	0.14	0.23	0.1	-0.43	0.29
Total Liab	0.57	0.21	-0.55	-0.71	-0.19		0.84	0.65	0.97	-0.09	0.57	0.01	-0.44	0.83	0.49	0.26	-0.16	0.62	-0.26	0.28	0.43	-0.67	0.5	0.75	-0.25
Total Current Assets	0.77	0.51	-0.65	-0.71	-0.07	0.84		0.72	0.77	-0.27	0.45	0.3	-0.67	0.54	0.69	0.53	-0.07	0.75	-0.1	0.3	0.41	-0.59	0.66	0.58	-0.18
Common Stock	0.82	0.69	-0.57	-0.97	-0.11	0.65	0.72		0.59	-0.23	0.44	0.5	-0.84	0.59	0.91	0.71	-0.22	0.23	-0.14	0.32	0.56	-0.81	0.11	0.77	-0.46
Current Deferred Revenue	0.48	0.14	-0.58	-0.67	-0.31	0.97	0.77	0.59		0.09	0.49	-0.04	-0.37	0.87	0.43	0.21	-0.14	0.56	-0.26	0.17	0.38	-0.66	0.38	0.77	-0.27
Short Term Debt	-0.45	-0.31	0.15	0.14	-0.38	-0.09	-0.27	-0.23	0.09		-0.01	-0.39	0.43	0.28	-0.3	-0.23	-0.29	-0.16	-0.42	-0.14	0.11	-0.15	-0.24	0.27	-0.11
Intangible Assets	0.15	-0.12	-0.17	-0.55	-0.17	0.57	0.45	0.44	0.49	-0.01		-0.39	-0.24	0.48	0.21	0.24	-0.08	0.29	-0.41	0.33	0.31	-0.5	0.31	0.61	-0.15
Net Tangible Assets	0.78	0.94	-0.25	-0.31	0.16	0.01	0.3	0.5	-0.04	-0.39	-0.39		-0.62	-0.16	0.71	0.49	-0.17	0.13	0.22	0.07	0.4	-0.13	0.05	-0.04	0.05
Capital Surpluse	-0.81	-0.71	0.57	0.79	-0.12	-0.44	-0.67	-0.84	-0.37	0.43	-0.24	-0.62		-0.24	-0.95	-0.75	-0.05	-0.2	-0.19	-0.26	-0.52	0.56	-0.1	-0.45	0.21
Deferred Long Term Liab	0.29	0.05	-0.45	-0.67	-0.41	0.83	0.54	0.59	0.87	0.28	0.48	-0.16	-0.24		0.33	0.13	-0.35	0.26	-0.48	0.18	0.31	-0.74	0.14	0.92	-0.59
Treasury Stock	0.87	0.83	-0.51	-0.84	0.05	0.49	0.69	0.91	0.43	-0.3	0.21	0.71	-0.95	0.33		0.77	-0.15	0.25	0.04	0.32	0.63	-0.68	0.12	0.55	-0.24
Property Plant Equipment	0.63	0.59	-0.3	-0.67	-0.07	0.26	0.53	0.71	0.21	-0.23	0.24	0.49	-0.75	0.13	0.77		0.27	0.17	0.33	0.32	0.45	-0.5	0.12	0.4	-0.23
Long Term Debt	-0.1	-0.3	-0.12	0.17	0.04	-0.16	-0.07	-0.22	-0.14	-0.29	-0.08	-0.17	-0.05	-0.35	-0.15	0.27		-0.14	0.88	-0.19	-0.18	0.41	-0.07	-0.33	0.15
Net Receivables	0.46	0.26	-0.31	-0.21	0.12	0.62	0.75	0.23	0.56	-0.16	0.29	0.13	-0.2	0.26	0.25	0.17	-0.14		-0.18	0.05	0.25	-0.2	0.87	0.18	0.15
Long Term Debt Total	0.09	0.01	-0.1	0.17	0.25	-0.26	-0.1	-0.14	-0.26	-0.42	-0.41	0.22	-0.19	-0.48	0.04	0.33	0.88	-0.18		-0.22	-0.08	0.41	-0.16	-0.46	0.21
Short Term Investments	0.23	0.21	0.37	-0.34	-0.01	0.28	0.3	0.32	0.17	-0.14	0.33	0.07	-0.26	0.18	0.32	0.32	-0.19	0.05	-0.22		0.3	-0.42	0.26	0.26	0.13
Short Long Term Debt	0.58	0.54	-0.13	-0.52	0.14	0.43	0.41	0.56	0.38	0.11	0.31	0.4	-0.52	0.31	0.63	0.45	-0.18	0.25	-0.08	0.3		-0.44	0.24	0.46	-0.04
Net Invested Capital	-0.43	-0.34	0.36	0.88	0.23	-0.67	-0.59	-0.81	-0.66	-0.15	-0.5	-0.13	0.56	-0.74	-0.68	-0.5	0.41	-0.2	0.41	-0.42	-0.44		-0.02	-0.87	0.42
Net Working Capital	0.38	0.2	-0.12	-0.07	0.1	0.5	0.66	0.11	0.38	-0.24	0.31	0.05	-0.1	0.14	0.12	0.12	-0.07	0.87	-0.16	0.26	0.24	-0.02		0.09	0.15
Capital Stock	0.39	0.22	-0.49	-0.84	-0.43	0.75	0.58	0.77	0.77	0.27	0.61	-0.04	-0.45	0.92	0.55	0.4	-0.33	0.18	-0.46	0.26	0.46	-0.87	0.09		-0.62
Good Will	-0.14	-0.09	0.41	0.46	0.29	-0.25	-0.18	-0.46	-0.27	-0.11	-0.15	0.05	0.21	-0.59	-0.24	-0.23	0.15	0.15	0.21	0.13	-0.04	0.42	0.15	-0.62

Click cells to compare fundamentals

About Lineage Cell Financial Statements

Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Debt Ratio	0.02	0.02
Cash Flow To Debt Ratio	(9.19)	(9.64)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lineage Debt Ratio from 2010 to 2025

Latest Lineage Cell's Debt Ratio Growth Pattern

Lineage Debt Ratio Regression Statistics

Lineage Debt Ratio History

Other Fundumenentals of Lineage Cell Therapeutics

Lineage Cell Debt Ratio component correlations

About Lineage Cell Financial Statements

Also Currently Popular

Additional Tools for Lineage Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY